Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP294324.RAXAnyIV88_j30f2KjxbCVRIOuP8Y21hWgn6q2FRFF1DE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP294324.RAXAnyIV88_j30f2KjxbCVRIOuP8Y21hWgn6q2FRFF1DE130_assertion type Assertion NP294324.RAXAnyIV88_j30f2KjxbCVRIOuP8Y21hWgn6q2FRFF1DE130_head.
- NP294324.RAXAnyIV88_j30f2KjxbCVRIOuP8Y21hWgn6q2FRFF1DE130_assertion description "[Subsequent AMKL evolves from a pre-existing TAM clone through the acquisition of additional mutations, with major mutational targets including multiple cohesin components (53%), CTCF (20%), and EZH2, KANSL1 and other epigenetic regulators (45%), as well as common signaling pathways, such as the JAK family kinases, MPL, SH2B3 (LNK) and multiple RAS pathway genes (47%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP294324.RAXAnyIV88_j30f2KjxbCVRIOuP8Y21hWgn6q2FRFF1DE130_provenance.
- NP294324.RAXAnyIV88_j30f2KjxbCVRIOuP8Y21hWgn6q2FRFF1DE130_assertion evidence source_evidence_literature NP294324.RAXAnyIV88_j30f2KjxbCVRIOuP8Y21hWgn6q2FRFF1DE130_provenance.
- NP294324.RAXAnyIV88_j30f2KjxbCVRIOuP8Y21hWgn6q2FRFF1DE130_assertion SIO_000772 24056718 NP294324.RAXAnyIV88_j30f2KjxbCVRIOuP8Y21hWgn6q2FRFF1DE130_provenance.
- NP294324.RAXAnyIV88_j30f2KjxbCVRIOuP8Y21hWgn6q2FRFF1DE130_assertion wasDerivedFrom befree-20140225 NP294324.RAXAnyIV88_j30f2KjxbCVRIOuP8Y21hWgn6q2FRFF1DE130_provenance.
- NP294324.RAXAnyIV88_j30f2KjxbCVRIOuP8Y21hWgn6q2FRFF1DE130_assertion wasGeneratedBy ECO_0000203 NP294324.RAXAnyIV88_j30f2KjxbCVRIOuP8Y21hWgn6q2FRFF1DE130_provenance.